Loading
Virus-based Gene Therapy Research / RNA Interference and Gene Delivery / CRISPR and Genetic Engineering · Journal article
Theoretical and Natural Science · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing preclinical literature on nanocarrier-mediated CRISPR/Cas9 delivery systems for tumour therapy. It identifies technical bottlenecks in translational development—including low cargo loading and inadequate intratumoural enrichment—and proposes future research directions, but reports no original empirical data, clinical trials, or quantified comparative efficacy.
Journal article.
Conventional gene editing delivery systems suffer from poor blood circulation stability, weak tumour-targeting, and off-target immunogenicity limiting clinical application Nanocarriers enhance in vivo transport and intracellular endosomal escape efficiency of CRISPR components, but multiple translational bottlenecks persist Critical unresolved issues include low cargo loading efficiency and inadequate intratumoural enrichment after intravenous injection
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
A narrative review of preclinical literature synthesizing nanocarrier design and CRISPR delivery mechanisms, raising research directions rather than reporting original empirical evidence or clinical outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Conventional gene editing delivery systems are plagued by poor long-term blood circulation stability, weak active tumour-targeting capability, and severe off-target immunogenicity after systemic intravenous administration, greatly restricting the widespread clinical application of precise minimally invasive malignant tumour therapy. This paper reviews considerable recent preclinical literature to systematically summarize the classification, physicochemical properties, and diverse fabrication techniques of mainstream lipid, polymeric, and inorganic nanocarriers. It further elaborates the core working mechanisms of CRISPR/Cas9 gene editing and several types of nanomaterial-assisted delivery platforms, and comprehensively compares their in vivo antitumour performance along with distinct respective merits and unavoidable inherent biological drawbacks. While nanocarriers substantially enhance the systemic in vivo transport and intracellular endosomal escape delivery efficiency of CRISPR gene-editing components, multiple critical translational bottlenecks still persist, including low cargo loading efficiency and inadequate intratumoural enrichment after intravenous injection. This review sorts out such core technical bottlenecks and highlights prospective research directions, such as multifunctional unified carriers and tumour microenvironment-responsive targeted delivery designs, which provides reliable systematic theoretical support for the subsequent clinical translation of nanomaterial-mediated gene editing against various malignancies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.